Ohio Code § 3701.76

§ 3701.76.

(A) The director of health shall establish and maintain a statewide public information

campaign on the effects of diethylstilbestrol or other nonsteroidal synthetic estrogens

for the purpose of educating the public concerning the potential hazards related to

exposure to diethylstilbestrol or other nonsteroidal synthetic estrogens and encouraging

persons exposed to diethylstilbestrol or other nonsteroidal synthetic estrogens, including

those exposed before birth, to seek medical attention for the identification and treatment

of any conditions resulting from this exposure. (B) The director shall maintain a registry of hospitals, clinics, physicians, certified

nurse-midwives, clinical nurse specialists, certified nurse practitioners, or other

health care providers to whom the director shall refer persons who make inquiries

to the department of health regarding possible exposure to diethylstilbestrol or other

nonsteroidal synthetic estrogens.  In order to be eligible for listing in the registry, a health care provider shall

make an application to the director, and shall have the necessary experience, facilities,

and equipment to make examinations for possible effects of diethylstilbestrol or other

nonsteroidal synthetic estrogens. (C) The director shall maintain a registry of persons who have been exposed to diethylstilbestrol

or other nonsteroidal synthetic estrogens, including persons exposed before birth,

for the purpose of studying and monitoring conditions caused by exposure to diethylstilbestrol

or other nonsteroidal synthetic estrogen.  No person shall be listed in the registry without the director's consent. (D) The director shall make an annual report to the general assembly on the effectiveness

of the programs established under this section, and shall make recommendations concerning

the programs and possible legislation relating to them. (E) No insurance company doing business under Title XXXIX and no health insuring corporation

holding a certificate of authority under Chapter 1751. of the Revised Code shall cancel

or refuse to renew a policy, contract, certificate, or agreement or limit benefits

provided under a policy, contract, certificate, or agreement solely because a policyholder,

subscriber, or applicant for a policy, contract, certificate, or agreement has been

exposed to diethylstilbestrol or other nonsteroidal synthetic estrogens.